Herantis Pharma (HRNTS) Company Presentation summary

Executive summary

• Developing HER-096, a disease-modifying peptide for Parkinson's disease (PD) and other CNS disorders, with strong preclinical and early clinical data showing neurorestorative effects and brain penetration.

• Phase 1a trial showed HER-096 is safe, well-tolerated, and achieves pharmacologically active levels in the brain; Phase 1b trial in PD patients is ongoing with topline data expected in Q3 2025.

• HER-096 targets the Unfolded Protein Response pathway, reduces toxic α-synuclein aggregates, alleviates neuroinflammation, and restores dopamine neuron function, addressing a major unmet need in PD.

• Preclinical and clinical proof-of-concept studies with CDNF (the protein HER-096 mimics) demonstrated significant motor function improvement and neuroprotection in animal models and advanced PD patients.

• HER-096 is administered subcutaneously, offering a patient-friendly alternative to current symptomatic treatments, with no observed systemic toxicity or serious adverse events.

Market opportunity and funding

• PD therapeutics market projected to reach $10B+ in target geographies by 2030, with HER-096 aiming for a 20% market share and $2B in annual revenue.

• Significant unmet need: over 328,000 new PD diagnoses yearly in target regions, and no existing disease-modifying or neurorestorative therapies.

• HER-096 has potential applications in ALS, Alzheimer's, and stroke, based on CDNF's demonstrated effects in preclinical models.

• Secured €6.1M in non-dilutive research funding since April 2023, including €3.6M from Michael J. Fox Foundation and Parkinson's UK, and €2.5M EIC Accelerator grant; €15M investment commitment from EIB.

Clinical and business development

• Phase 1b trial started in September 2024, with multiple dosing in PD patients; Phase 2 trial preparation underway for 2026.

• 75 partnering meetings held with 55 pharma targets; key triggers for partnership include Phase 1b data and readiness for Phase 2.

• Executive team and board have extensive experience in neuroscience, drug development, and biotech business leadership.

• HER-096's differentiated mechanism and administration position it as a first-in-class, disease-modifying, neuroregenerative therapy for PD.